Great Debate: SGLT2 inhibitors should be first-line treatment in heart failure with reduced ejection fraction

被引：2
|
作者：
Packer, Milton [1 ,2 ]
Cleland, John G. F. [3 ]
Bauersachs, Johann [4 ]
机构：
[1] Baylor Heart & Vasc Inst, Dallas, TX USA
[2] Imperial Coll, London, England
[3] Univ Glasgow, British Heart Fdn Ctr Res Excellence, Sch Cardiovasc & Metab Hlth, Glasgow, Scotland
[4] Hannover Med Sch, Dept Cardiol & Angiol, Carl Neuberg Str 1, D-30625 Hannover, Germany
来源：
EUROPEAN HEART JOURNAL | 2024年 / 45卷 / 25期
关键词：
Heart failure; SGLT2; inhibitor; Pharmacotherapy; Foundational drugs; Hospitalization; EMPAGLIFLOZIN; RISK; DAPAGLIFLOZIN; HYPERTENSION; METAANALYSIS; DIURETICS; MORTALITY; MEDICINE; BENEFITS; OUTCOMES;
D O I：
10.1093/eurheartj/ehae300
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Graphical Abstract SGLT2 inhibitors should be first-line treatment in heart failure with reduced ejection fraction. ARNI, angiotensin receptor-neprilysin inhibitor; CV, cardiovascular; GRMT, guideline-recommended medical therapy; HF, heart failure; HFrEF, heart failure with reduced ejection fraction; MRA, mineralocorticoid receptor antagonist; SGLT2i, sodium-glucose cotransporter 2 inhibitor.
引用
收藏
页码：2186 / 2196
页数：11
相关论文
共 50 条
  • [31] Do sglt2 inhibitors improve survival in heart failure with any ejection fraction?
    Yi, Ko
    Wong, Suzanne
    Wong, Kenneth
    Al-riyahi, Mohammad
    HEART, 2023, 109 : A175 - A177
  • [32] Are SGLT2 inhibitors effective against 'all' heart failure with preserved ejection fraction?
    Hasegawa, Koji
    Lewis, Basil S.
    EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, 2022,
  • [33] Emerging Horizons in Heart Failure with Preserved Ejection Fraction: The Role of SGLT2 Inhibitors
    Rebecca Heath
    Håkon Johnsen
    W. David Strain
    Marc Evans
    Diabetes Therapy, 2022, 13 : 241 - 250
  • [34] EMPEROR-Reduced supports the use of SGLT2 inhibitors for the treatment of patients with heart failure and reduced ejection fraction: Comment on the EMPEROR-Reduced trial
    Liuzzo, Giovanna
    Patrono, Carlo
    EUROPEAN HEART JOURNAL, 2020, 41 (40) : 3881 - 3882
  • [35] Eligibility and prescribing rates of SGLT2 inhibitors for ambulatory patients with heart failure and reduced ejection fraction in a multidisciplinary heart failure management programme
    Nadarajah, R.
    Younis, A.
    Aktaa, S.
    Gale, C. P.
    EUROPEAN HEART JOURNAL, 2023, 44
  • [36] The Impact of SGLT2 Inhibitors on Cardiovascular Outcomes in Patients With Heart Failure With Preserved Ejection Fraction
    Starr, Jessica A.
    Pinner, Nathan A.
    ANNALS OF PHARMACOTHERAPY, 2024, 58 (05) : 506 - 513
  • [37] SGLT2 Inhibitors for Heart Failure with Preserved Ejection Fraction: What Hospitalists Need to Know
    Stephen J. Greene
    Gregg C. Fonarow
    Javed Butler
    American Journal of Cardiovascular Drugs, 2024, 24 : 1 - 4
  • [38] SGLT2 Inhibitors for Heart Failure with Preserved Ejection Fraction: What Hospitalists Need to Know
    Greene, Stephen J.
    Fonarow, Gregg C.
    Butler, Javed
    AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2024, 24 (01) : 1 - 4
  • [39] SGLT2 inhibitors: further evidence for heart failure with preserved ejection fraction as a metabolic disease?
    Echouffo-Tcheugui, Justin B.
    Lewsey, Sabra C.
    Weiss, Robert G.
    JOURNAL OF CLINICAL INVESTIGATION, 2021, 131 (23):
  • [40] SGLT2 inhibitors in real-world patients with heart failure with preserved ejection fraction
    Tarantini, R.
    Vecchi, A. L.
    Matteo, F.
    De Ponti, R.
    Mortara, A.
    EUROPEAN HEART JOURNAL, 2022, 43 : 779 - 779
12345